These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26210957)

  • 1. Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.
    Devoldere J; Dewitte H; De Smedt SC; Remaut K
    Drug Discov Today; 2016 Jan; 21(1):11-25. PubMed ID: 26210957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.
    Guan S; Rosenecker J
    Gene Ther; 2017 Mar; 24(3):133-143. PubMed ID: 28094775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics.
    Muslimov A; Tereshchenko V; Shevyrev D; Rogova A; Lepik K; Reshetnikov V; Ivanov R
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across.
    Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K
    Adv Drug Deliv Rev; 2021 Sep; 176():113900. PubMed ID: 34324884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Transcribed mRNA Vaccines with Programmable Stimulation of Innate Immunity.
    Loomis KH; Lindsay KE; Zurla C; Bhosle SM; Vanover DA; Blanchard EL; Kirschman JL; Bellamkonda RV; Santangelo PJ
    Bioconjug Chem; 2018 Sep; 29(9):3072-3083. PubMed ID: 30067354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy.
    Jolly KJ; Zhang F
    Adv Pharmacol; 2024; 100():247-288. PubMed ID: 39034054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint.
    Granot Y; Peer D
    Semin Immunol; 2017 Dec; 34():68-77. PubMed ID: 28890238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
    Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
    J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA transcript therapy.
    Weissman D
    Expert Rev Vaccines; 2015 Feb; 14(2):265-81. PubMed ID: 25359562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA as a versatile tool for exogenous protein expression.
    Kuhn AN; Beiβert T; Simon P; Vallazza B; Buck J; Davies BP; Tureci O; Sahin U
    Curr Gene Ther; 2012 Oct; 12(5):347-61. PubMed ID: 22827224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.
    Steinle H; Behring A; Schlensak C; Wendel HP; Avci-Adali M
    Stem Cells; 2017 Jan; 35(1):68-79. PubMed ID: 27250673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration.
    Johler SM; Rejman J; Guan S; Rosenecker J
    PLoS One; 2015; 10(9):e0137504. PubMed ID: 26352268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of mRNA-based vaccines.
    Iavarone C; O'hagan DT; Yu D; Delahaye NF; Ulmer JB
    Expert Rev Vaccines; 2017 Sep; 16(9):871-881. PubMed ID: 28701102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
    Goldberg JL; Sondel PM
    Semin Oncol; 2015 Aug; 42(4):562-72. PubMed ID: 26320061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro.
    Broering R; Real CI; John MJ; Jahn-Hofmann K; Ickenstein LM; Kleinehr K; Paul A; Gibbert K; Dittmer U; Gerken G; Schlaak JF
    Int Immunol; 2014 Jan; 26(1):35-46. PubMed ID: 24065781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety.
    Vlatkovic I
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34068715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic mRNA delivery to leukocytes.
    Granot-Matok Y; Kon E; Dammes N; Mechtinger G; Peer D
    J Control Release; 2019 Jul; 305():165-175. PubMed ID: 31121277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA-Based Therapeutics - Advances and Perspectives.
    Sergeeva OV; Koteliansky VE; Zatsepin TS
    Biochemistry (Mosc); 2016 Jul; 81(7):709-22. PubMed ID: 27449617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs.
    Zhong Z; McCafferty S; Opsomer L; Wang H; Huysmans H; De Temmerman J; Lienenklaus S; Portela Catani JP; Combes F; Sanders NN
    Mol Ther; 2021 Apr; 29(4):1370-1381. PubMed ID: 33484964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal and early-life exposures alter expression of innate immunity genes: the PASTURE cohort study.
    Loss G; Bitter S; Wohlgensinger J; Frei R; Roduit C; Genuneit J; Pekkanen J; Roponen M; Hirvonen MR; Dalphin JC; Dalphin ML; Riedler J; von Mutius E; Weber J; Kabesch M; Michel S; Braun-Fahrländer C; Lauener R;
    J Allergy Clin Immunol; 2012 Aug; 130(2):523-30.e9. PubMed ID: 22846753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.